A Phase 1 interventional study of GSK3640254 and DTG in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-19.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing GSK3640254 in HIV Infections — none open to participants now, none under way, none of them phase 3. GSK3640254 · HIV Infections.
Among the 15 studies testing GSK3640254 in HIV Infections, this one is the 11th largest by enrollment, is one of 5 that started in 2019, is one of 12 in phase 1, and was the 4th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →None of the 15 studies testing GSK3640254 in HIV Infections is open now. The open studies under HIV Infections, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 34 across the 15 interventional studies. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 1 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 189th largest by enrollment of the 210 interventional ones that give a count, is one of 14 that started in 2019, is one of 83 in phase 1, and was the 197th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing GSK3640254 in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
This is an open-label, single-sequence, two-way drug interaction study to investigate the PK, safety and tolerability of GSK3640254 and DTG when administered alone or in combination in healthy subjects. Treatment of human immunodeficiency virus (HIV) infection frequently involves combination therapy. Data from this study will contribute to dosing recommendations when GSK3640254 and DTG are given in combination. The study will consist of a Screening period and 3 sequential treatment periods. Subjects will be administered DTG 50 milligrams (mg) once daily (QD) in Period 1 followed by GSK3640254 200 mg QD in Period 2. There will be a washout period of 4 days between Periods 1 and 2. In Period 3, subjects will be co-administered DTG 50 mg QD and GSK3640254 200 mg QD. The total duration of the study will be approximately 55 days, including Screening.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive DTG 50 mg QD on Days 1 through 5 in Period 1 followed by a wash-out period of 4 days. Subjects will then receive GSK3640254 200 mg QD on Days 1 through 7 in Period 2 followed by co-administration of DTG 50 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Period 3.
Drug: GSK3640254 · Drug: DTG
GSK3640254 will be available as 100 mg capsules. Subjects will be administered GSK3640254 200 mg QD via the oral route.
DTG will be available as 50 mg tablets. Subjects will be administered DTG 50 mg QD via the oral route.
Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing (AUC[0 to Tau]) of Dolutegravir for Dolutegravir Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis. Pharmacokinetic Parameter Population consisted of all participants who underwent plasma pharmacokinetic sampling and had evaluable pharmacokinetic parameters estimated.
Time frame: Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 3: AUC(0 to Tau) of Dolutegravir for Dolutegravir + GSK3640254 Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 7: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 1: Maximum Observed Concentration (Cmax) of Dolutegravir for Dolutegravir Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 3: Cmax of Dolutegravir for Dolutegravir + GSK3640254 Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 7: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of Dolutegravir for Dolutegravir Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 3: Ctau of Dolutegravir for Dolutegravir + GSK3640254 Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 7: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 2: AUC(0 to Tau) of GSK3640254 for GSK3640254 Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 3: AUC(0 to Tau) of GSK3640254 for Dolutegravir + GSK3640254 Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 2: Cmax of GSK3640254 for GSK3640254 Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 3: Cmax of GSK3640254 for Dolutegravir + GSK3640254 Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 2: Ctau of GSK3640254 for GSK3640254 Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 3: Ctau of GSK3640254 for Dolutegravir + GSK3640254 Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; and other important medical events which may require medical or surgical intervention. Safety Population consisted of all participants who received at least 1 dose of study medication.
Time frame: Up to Day 27
Period 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day -1) and at Day 9
Period 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 1 Day 9) and at Day 7
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Period 1: Change From Baseline in Hematology Parameter: Hemoglobin
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day -1) and at Day 9
Period 2: Change From Baseline in Hematology Parameter: Hemoglobin
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 1 Day 9) and at Day 7
Period 3: Change From Baseline in Hematology Parameter: Hemoglobin
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Period 1: Change From Baseline in Hematology Parameter: Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day -1) and at Day 9
Period 2: Change From Baseline in Hematology Parameter: Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 1 Day 9) and at Day 7
Period 3: Change From Baseline in Hematology Parameter: Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Period 1: Change From Baseline in Hematology Parameter: Erythrocytes
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day -1) and at Day 9
Period 2: Change From Baseline in Hematology Parameter: Erythrocytes
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 1 Day 9) and at Day 7
Period 3: Change From Baseline in Hematology Parameter: Erythrocytes
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day -1) and at Day 9
Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 1 Day 9) and at Day 7
Period 3: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day -1) and at Day 9
Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 1 Day 9) and at Day 7
Period 3: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Period 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen
Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day -1) and at Day 9
Period 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen
Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 1 Day 9) and at Day 7
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen
Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Period 1: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day -1) and at Day 9
Period 2: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 1 Day 9) and at Day 7
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Period 1: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day -1) and at Day 9
Period 2: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 1 Day 9) and at Day 7
Period 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Period 1: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day -1) and at Day 9
Period 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 1 Day 9) and at Day 7
Period 3: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Period 1: Change From Baseline in Chemistry Parameters: Amylase, Lipase
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day -1) and at Day 9
Period 2: Change From Baseline in Chemistry Parameters: Amylase, Lipase
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 1 Day 9) and at Day 7
Period 3: Change From Baseline in Chemistry Parameters: Amylase, Lipase
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Period 1: Change From Baseline in Urinalysis Parameter: Specific Gravity
Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day -1) and at Day 9
Period 2: Change From Baseline in Urinalysis Parameter: Specific Gravity
Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 1 Day 9) and at Day 7
Period 3: Change From Baseline in Urinalysis Parameter: Specific Gravity
Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Period 1: Change From Baseline in Urinalysis Parameter: Urobilinogen
Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day -1) and at Day 9
Period 2: Change From Baseline in Urinalysis Parameter: Urobilinogen
Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 1 Day 9) and at Day 7
Period 3: Change From Baseline in Urinalysis Parameter: Urobilinogen
Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Period 1: Change From Baseline in Urinalysis Parameter: Potential of Hydrogen (pH)
Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day -1) and at Day 9
Period 2: Change From Baseline in Urinalysis Parameter: pH
Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 1 Day 9) and at Day 7
Period 3: Change From Baseline in Urinalysis Parameter: pH
Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Period 1: Number of Participants With Urinalysis Dipstick Results
Urine samples were collected at indicated time points to analyze parameters including glucose, protein, occult blood, ketones, nitrite, bilirubin and leukocyte esterase levels by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace, 1+ (low concentrations present) and 2+ (moderate concentrations present) indicating proportional concentrations in the urine sample.
Time frame: Day 9
Period 2: Number of Participants With Urinalysis Dipstick Results
Urine samples were collected at indicated time points to analyze parameters including glucose, protein, occult blood, ketones, nitrite, bilirubin and leukocyte esterase levels by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace, 1+ (low concentrations present), and 2+ (moderate concentrations present) indicating proportional concentrations in the urine sample.
Time frame: Day 7
Period 3: Number of Participants With Urinalysis Dipstick Results
Urine samples were collected at indicated time points to analyze parameters including glucose, protein, occult blood, ketones, nitrite, bilirubin and leukocyte esterase levels by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace, 1+ (low concentrations present), and 2+ (moderate concentrations present)indicating proportional concentrations in the urine sample.
Time frame: Days 4, 7 and 10
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB)
Twelve-lead electrocardiograms (ECG) were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments on Day 1 of Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline, Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB
Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments on Day 1 of Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline; Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB
Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline; Day 1: 2 hours, 4 hours; Days 4, 5 and 7: Pre-dose, 2 hours and 4 hours; Day 10
Period 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
SBP and DBP were measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5
Period 2: Change From Baseline in SBP and DBP
SBP and DBP were measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7
Period 3: Change From Baseline in SBP and DBP
SBP and DBP were measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Period 1: Change From Baseline in Pulse Rate
Pulse rate was measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5
Period 2: Change From Baseline in Pulse Rate
Pulse rate was measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7
Period 3: Change From Baseline in Pulse Rate
Pulse rate was measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Period 1: Change From Baseline in Respiratory Rate
Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5
Period 2: Change From Baseline in Respiratory Rate
Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7
Period 3: Change From Baseline in Respiratory Rate
Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Period 1: Change From Baseline in Body Temperature
Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5
Period 2: Change From Baseline in Body Temperature
Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7
Period 3: Change From Baseline in Body Temperature
Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Period 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count.
Time frame: Day 9
Period 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count.
Time frame: Day 7
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count.
Time frame: Days 4, 7 and 10
Period 1: Absolute Values for Hematology Parameter: Hemoglobin
Blood samples were collected to analyze the hematology parameter: hemoglobin.
Time frame: Day 9
Period 2: Absolute Values for Hematology Parameter: Hemoglobin
Blood samples were collected to analyze the hematology parameter: hemoglobin.
Time frame: Day 7
Period 3: Absolute Values for Hematology Parameter: Hemoglobin
Blood samples were collected to analyze the hematology parameter: hemoglobin.
Time frame: Days 4, 7 and 10
Period 1: Absolute Values for Hematology Parameter: Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit.
Time frame: Day 9
Period 2: Absolute Values for Hematology Parameter: Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit.
Time frame: Day 7
Period 3: Absolute Values for Hematology Parameter: Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit.
Time frame: Days 4, 7 and 10
Period 1: Absolute Values for Hematology Parameter: Erythrocytes
Blood samples were collected to analyze the hematology parameter: erythrocytes.
Time frame: Day 9
Period 2: Absolute Values for Hematology Parameter: Erythrocytes
Blood samples were collected to analyze the hematology parameter: erythrocytes.
Time frame: Day 7
Period 3: Absolute Values for Hematology Parameter: Erythrocytes
Blood samples were collected to analyze the hematology parameter: erythrocytes.
Time frame: Days 4, 7 and 10
Period 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.
Time frame: Day 9
Period 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.
Time frame: Day 7
Period 3: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.
Time frame: Days 4, 7 and 10
Period 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.
Time frame: Day 9
Period 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.
Time frame: Day 7
Period 3: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.
Time frame: Days 4, 7 and 10
Period 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen
Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.
Time frame: Day 9
Period 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen
Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.
Time frame: Day 7
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen
Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.
Time frame: Days 4, 7 and 10
Period 1: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.
Time frame: Day 9
Period 2: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.
Time frame: Day 7
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.
Time frame: Days 4, 7 and 10
Period 1: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.
Time frame: Day 9
Period 2: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.
Time frame: Day 7
Period 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.
Time frame: Days 4, 7 and 10
Period 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.
Time frame: Day 9
Period 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.
Time frame: Day 7
Period 3: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.
Time frame: Days 4, 7 and 10
Period 1: Absolute Values for Chemistry Parameters: Amylase, Lipase
Blood samples were collected to analyze the chemistry parameters: amylase and lipase.
Time frame: Day 9
Period 2: Absolute Values for Chemistry Parameters: Amylase, Lipase
Blood samples were collected to analyze the chemistry parameters: amylase and lipase.
Time frame: Day 7
Period 3: Absolute Values for Chemistry Parameters: Amylase, Lipase
Blood samples were collected to analyze the chemistry parameters: amylase and lipase.
Time frame: Days 4, 7 and 10
Period 1: Absolute Values for Urinalysis Parameter: Specific Gravity
Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.
Time frame: Day 9
Period 2: Absolute Values for Urinalysis Parameter: Specific Gravity
Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.
Time frame: Day 7
Period 3: Absolute Values for Urinalysis Parameter: Specific Gravity
Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.
Time frame: Days 4, 7 and 10
Period 1: Absolute Values for Urinalysis Parameter: Urobilinogen
Urine samples were collected to analyze the urinalysis parameter: urobilinogen.
Time frame: Day 9
Period 2: Absolute Values for Urinalysis Parameter: Urobilinogen
Urine samples were collected to analyze the urinalysis parameter: urobilinogen.
Time frame: Day 7
Period 3: Absolute Values for Urinalysis Parameter: Urobilinogen
Urine samples were collected to analyze the urinalysis parameter: urobilinogen.
Time frame: Days 4, 7 and 10
Period 1: Absolute Values for Urinalysis Parameter: pH
Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).
Time frame: Day 9
Period 2: Absolute Values for Urinalysis Parameter: pH
Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).
Time frame: Day 7
Period 3: Absolute Values for Urinalysis Parameter: pH
Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).
Time frame: Days 4, 7 and 10
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB
Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.
Time frame: Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB
Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.
Time frame: Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB
Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.
Time frame: Day 1: 2 hours, 4 hours; Days 4, 5 and 7: Pre-dose, 2 hours and 4 hours; Day 10
Period 1: Absolute Values for SBP and DBP
SBP and DBP were measured in the semi-recumbent position with a completely automated device.
Time frame: Days 2, 3, 4 and 5
Period 2: Absolute Values for SBP and DBP
SBP and DBP were measured in the semi-recumbent position with a completely automated device.
Time frame: Days 2, 3, 4, 5, 6 and 7
Period 3: Absolute Values for SBP and DBP
SBP and DBP were measured in the semi-recumbent position with a completely automated device.
Time frame: Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Period 1: Absolute Values for Pulse Rate
Pulse rate was measured in the semi-recumbent position with a completely automated device.
Time frame: Days 2, 3, 4 and 5
Period 2: Absolute Values for Pulse Rate
Pulse rate was measured in the semi-recumbent position with a completely automated device.
Time frame: Days 2, 3, 4, 5, 6 and 7
Period 3: Absolute Values for Pulse Rate
Pulse rate was measured in the semi-recumbent position with a completely automated device.
Time frame: Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Period 1: Absolute Values for Respiratory Rate
Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.
Time frame: Days 2, 3, 4 and 5
Period 2: Absolute Values for Respiratory Rate
Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.
Time frame: Days 2, 3, 4, 5, 6 and 7
Period 3: Absolute Values for Respiratory Rate
Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.
Time frame: Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Period 1: Absolute Values for Body Temperature
Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.
Time frame: Days 2, 3, 4 and 5
Period 2: Absolute Values for Body Temperature
Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.
Time frame: Days 2, 3, 4, 5, 6 and 7
Period 3: Absolute Values for Body Temperature
Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.
Time frame: Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Period 2: Time of Maximum Observed Concentration (Tmax) of GSK3640254 for GSK3640254 Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 3: Tmax of GSK3640254 for Dolutegravir + GSK3640254 Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 2: Apparent Terminal Phase Half-life (T1/2) of GSK3640254 for GSK3640254 Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis. Data could not be determined due to limited sampling points after final dosing (during elimination phase). An accurate determination of GSK3640254 half-life would require sampling up to 3 times half-life (3 \* approximately 24 hours). However sampling in Period 2 was performed up to only 24 hours post-dose.
Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 3: T1/2 of GSK3640254 for Dolutegravir + GSK3640254 Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 1: Tmax of Dolutegravir for Dolutegravir Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 3: Tmax of Dolutegravir for Dolutegravir + GSK3640254 Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 1: T1/2 of Dolutegravir for Dolutegravir Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Period 3: T1/2 of Dolutegravir for Dolutegravir + GSK3640254 Arm
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
This was an open-label, fixed-sequence, two-way drug interaction and 3-period study. Participants received treatment A- dolutegravir 50 milligram (mg) in Period 1; treatment B- GSK3640254 200 mg in Period 2 and treatment C- dolutegravir 50 mg and GSK3640254 200 mg in Period 3.
| Milestone | Dolutegravir/GSK3640254/Dolutegravir+GSK3640254 |
|---|---|
| Started | 16 |
| Completed | 16 |
| Not completed | 0 |
| Milestone | Dolutegravir/GSK3640254/Dolutegravir+GSK3640254 |
|---|---|
| Started | 16 |
| Completed | 16 |
| Not completed | 0 |
| Milestone | Dolutegravir/GSK3640254/Dolutegravir+GSK3640254 |
|---|---|
| Started | 16 |
| Completed | 16 |
| Not completed | 0 |
| Milestone | Dolutegravir/GSK3640254/Dolutegravir+GSK3640254 |
|---|---|
| Started | 16 |
| Completed | 16 |
| Not completed | 0 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis. Pharmacokinetic Parameter Population consisted of all participants who underwent plasma pharmacokinetic sampling and had evaluable pharmacokinetic parameters estimated.
| Hours* nanogram per milliliter | Dolutegravir 50 mg |
|---|---|
| Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing (AUC[0 to Tau]) of Dolutegravir for Dolutegravir Arm | 64627.8 ± 20.1 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Hours* nanogram per milliliter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Period 3: AUC(0 to Tau) of Dolutegravir for Dolutegravir + GSK3640254 Arm | 75860.5 ± 22.7 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | Dolutegravir 50 mg |
|---|---|
| Period 1: Maximum Observed Concentration (Cmax) of Dolutegravir for Dolutegravir Arm | 4962 ± 16.5 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Period 3: Cmax of Dolutegravir for Dolutegravir + GSK3640254 Arm | 5408 ± 17.2 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | Dolutegravir 50 mg |
|---|---|
| Period 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of Dolutegravir for Dolutegravir Arm | 1373 ± 30.6 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Period 3: Ctau of Dolutegravir for Dolutegravir + GSK3640254 Arm | 1696 ± 31.1 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Hours* microgram per milliliter | GSK3640254 200 mg |
|---|---|
| Period 2: AUC(0 to Tau) of GSK3640254 for GSK3640254 Arm | 26.72 ± 32.3 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Hours* microgram per milliliter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Period 3: AUC(0 to Tau) of GSK3640254 for Dolutegravir + GSK3640254 Arm | 27.84 ± 30.1 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Microgram per milliliter | GSK3640254 200 mg |
|---|---|
| Period 2: Cmax of GSK3640254 for GSK3640254 Arm | 1.676 ± 26.4 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Microgram per milliliter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Period 3: Cmax of GSK3640254 for Dolutegravir + GSK3640254 Arm | 1.662 ± 26.8 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Microgram per milliliter | GSK3640254 200 mg |
|---|---|
| Period 2: Ctau of GSK3640254 for GSK3640254 Arm | 0.8583 ± 38.3 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Microgram per milliliter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Period 3: Ctau of GSK3640254 for Dolutegravir + GSK3640254 Arm | 0.8549 ± 34.1 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; and other important medical events which may require medical or surgical intervention. Safety Population consisted of all participants who received at least 1 dose of study medication.
| Participants | Dolutegravir 50 mg | GSK3640254 200 mg | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|---|---|
| Non-SAEs | 1 | 3 | 2 |
| SAEs | 0 | 0 | 0 |
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| 10^9 cells per liter | Dolutegravir 50 mg |
|---|---|
| Basophils | -0.003 ± 0.0124 |
| Eosinophils | 0.046 ± 0.1198 |
| Lymphocytes | 0.013 ± 0.3793 |
| Monocytes | -0.020 ± 0.0829 |
| Neutrophils | -0.217 ± 0.6421 |
| Platelet count | -6.5 ± 21.73 |
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| 10^9 cells per liter | GSK3640254 200 mg |
|---|---|
| Basophils | -0.006 ± 0.0089 |
| Eosinophils | -0.026 ± 0.0810 |
| Lymphocytes | -0.154 ± 0.2718 |
| Monocytes | -0.024 ± 0.0701 |
| Neutrophils | -0.160 ± 0.3762 |
| Platelet count | -6.0 ± 30.58 |
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| 10^9 cells per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4: Basophils, n=16 | 0.003 ± 0.0101 |
| Day 7: Basophils, n=16 | 0.007 ± 0.0135 |
| Day 10: Basophils, n=16 | 0.003 ± 0.0144 |
| Day 4: Eosinophils, n=16 | -0.001 ± 0.0448 |
| Day 7: Eosinophils, n=16 | 0.004 ± 0.0846 |
| Day 10: Eosinophils, n=16 | -0.036 ± 0.0468 |
| Day 4: Lymphocytes, n=16 | -0.130 ± 0.2931 |
| Day 7: Lymphocytes, n=16 | -0.033 ± 0.3260 |
| Day 10: Lymphocytes, n=16 | -0.117 ± 0.2628 |
| Day 4: Monocytes, n=16 | 0.049 ± 0.1627 |
| Day 7: Monocytes, n=16 | 0.003 ± 0.0850 |
| Day 10: Monocytes, n=16 | -0.018 ± 0.0693 |
| Day 4: Neutrophils, n=16 | 0.443 ± 1.5098 |
| Day 7: Neutrophils, n=16 | 0.076 ± 0.5969 |
| Day 10: Neutrophils, n=16 | 0.204 ± 0.5116 |
| Day 4: Platelet count, n=16 | -4.9 ± 11.08 |
| Day 7: Platelet count, n=15 | -11.5 ± 12.03 |
| Day 10: Platelet count, n=16 | -5.9 ± 16.50 |
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Grams per liter | Dolutegravir 50 mg |
|---|---|
| Period 1: Change From Baseline in Hematology Parameter: Hemoglobin | 4.4 ± 5.97 |
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Grams per liter | GSK3640254 200 mg |
|---|---|
| Period 2: Change From Baseline in Hematology Parameter: Hemoglobin | 0.1 ± 2.53 |
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Grams per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 3.3 ± 3.00 |
| Day 7 | 0.6 ± 3.50 |
| Day 10 | 1.2 ± 3.69 |
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Proportion of red blood cells in blood | Dolutegravir 50 mg |
|---|---|
| Period 1: Change From Baseline in Hematology Parameter: Hematocrit | 0.0178 ± 0.01988 |
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Proportion of red blood cells in blood | GSK3640254 200 mg |
|---|---|
| Period 2: Change From Baseline in Hematology Parameter: Hematocrit | -0.0013 ± 0.00948 |
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Proportion of red blood cells in blood | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 0.0035 ± 0.00794 |
| Day 7 | -0.0049 ± 0.01101 |
| Day 10 | -0.0041 ± 0.01402 |
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Trillion cells per liter | Dolutegravir 50 mg |
|---|---|
| Period 1: Change From Baseline in Hematology Parameter: Erythrocytes | 0.170 ± 0.2080 |
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Trillion cells per liter | GSK3640254 200 mg |
|---|---|
| Period 2: Change From Baseline in Hematology Parameter: Erythrocytes | 0.036 ± 0.1020 |
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Trillion cells per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 0.016 ± 0.0943 |
| Day 7 | -0.079 ± 0.1038 |
| Day 10 | -0.054 ± 0.1540 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Femtoliter | Dolutegravir 50 mg |
|---|---|
| Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume | 0.63 ± 0.774 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Femtoliter | GSK3640254 200 mg |
|---|---|
| Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume | -0.86 ± 0.564 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Femtoliter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 0.40 ± 0.542 |
| Day 7 | 0.36 ± 0.762 |
| Day 10 | 0.05 ± 0.954 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Picograms | Dolutegravir 50 mg |
|---|---|
| Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin | -0.11 ± 0.279 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Picograms | GSK3640254 200 mg |
|---|---|
| Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin | -0.17 ± 0.218 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Picograms | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 0.55 ± 0.225 |
| Day 7 | 0.55 ± 0.329 |
| Day 10 | 0.52 ± 0.315 |
Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Millimoles per liter | Dolutegravir 50 mg |
|---|---|
| Glucose | 0.063 ± 0.4235 |
| Cholesterol | 0.088 ± 0.6858 |
| Triglycerides | -0.084 ± 0.3983 |
| Anion gap | -1.2 ± 1.33 |
| Calcium | 0.025 ± 0.0599 |
| Carbon dioxide | -0.1 ± 2.03 |
| Chloride | 1.6 ± 2.63 |
| Phosphate | 0.091 ± 0.1531 |
| Potassium | 0.05 ± 0.356 |
| Sodium | 0.3 ± 2.15 |
| Blood urea nitrogen | 0.297 ± 0.9823 |
Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Millimoles per liter | GSK3640254 200 mg |
|---|---|
| Glucose | -0.249 ± 0.1748 |
| Cholesterol | -0.269 ± 0.2363 |
| Triglycerides | 0.087 ± 0.2374 |
| Anion gap | 2.2 ± 1.52 |
| Calcium | 0.014 ± 0.0245 |
| Carbon dioxide | -1.3 ± 1.53 |
| Chloride | -0.7 ± 1.78 |
| Phosphate | 0.037 ± 0.0955 |
| Potassium | -0.03 ± 0.272 |
| Sodium | 0.3 ± 1.74 |
| Blood urea nitrogen | -0.341 ± 0.3937 |
Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Millimoles per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4: Glucose | 0.062 ± 0.1638 |
| Day 7: Glucose | 0.103 ± 0.1806 |
| Day 10: Glucose | -0.066 ± 0.2205 |
| Day 4: Cholesterol | 0.096 ± 0.2400 |
| Day 7: Cholesterol | -0.008 ± 0.2693 |
| Day 10: Cholesterol | -0.030 ± 0.2366 |
| Day 4: Triglycerides | 0.034 ± 0.2316 |
| Day 7: Triglycerides | -0.094 ± 0.2578 |
| Day 10: Triglycerides | 0.095 ± 0.2178 |
| Day 4: Anion gap | -4.1 ± 1.24 |
| Day 7: Anion gap | 0.1 ± 1.69 |
| Day 10: Anion gap | 0.8 ± 1.65 |
| Day 4: Calcium | -0.003 ± 0.0416 |
| Day 7: Calcium | 0.026 ± 0.0413 |
| Day 10: Calcium: | 0.035 ± 0.0561 |
| Day 4: Carbon dioxide | 0.9 ± 1.65 |
| Day 7: Carbon dioxide | 0.1 ± 1.59 |
| Day 10: Carbon dioxide | 1.0 ± 2.16 |
| Day 4: Chloride | 0.7 ± 1.92 |
| Day 7: Chloride | -0.3 ± 1.39 |
| Day 10: Chloride | -1.1 ± 1.86 |
| Day 4: Phosphate | -0.004 ± 0.0808 |
| Day 7: Phosphate | -0.013 ± 0.1151 |
| Day 10: Phosphate | -0.051 ± 0.1115 |
| Day 4: Potassium | -0.04 ± 0.239 |
| Day 7: Potassium | -0.03 ± 0.218 |
| Day 10: Potassium | 0.06 ± 0.189 |
| Day 4: Sodium | -2.0 ± 1.37 |
| Day 7: Sodium | -0.1 ± 1.65 |
| Day 10: Sodium | 0.5 ± 1.90 |
| Day 4: Blood urea nitrogen | 0.054 ± 0.5287 |
| Day 7: Blood urea nitrogen | -0.178 ± 0.3542 |
| Day 10: Blood urea nitrogen | -0.026 ± 0.5156 |
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| International units per liter | Dolutegravir 50 mg |
|---|---|
| Creatine kinase | -32.0 ± 61.33 |
| Lactate dehydrogenase | -21.9 ± 14.16 |
| ALT | -0.3 ± 8.28 |
| ALP | -0.1 ± 7.67 |
| AST | -0.7 ± 3.36 |
| Gamma-glutamyl transferase | -2.1 ± 3.13 |
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| International units per liter | GSK3640254 200 mg |
|---|---|
| Creatine kinase | 22.6 ± 58.21 |
| Lactate dehydrogenase | 9.1 ± 5.76 |
| ALT | -0.6 ± 2.80 |
| ALP | 1.9 ± 2.70 |
| AST | 0.2 ± 1.87 |
| Gamma-glutamyl transferase | -0.8 ± 1.28 |
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| International units per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4: Creatine kinase | -32.1 ± 131.30 |
| Day 7: Creatine kinase | -37.1 ± 158.35 |
| Day 10: Creatine kinase | -42.1 ± 162.94 |
| Day 4: Lactate dehydrogenase | 5.9 ± 7.38 |
| Day 7: Lactate dehydrogenase | -0.9 ± 7.02 |
| Day 10: Lactate dehydrogenase | 0.1 ± 10.32 |
| Day 4: ALT | 1.1 ± 4.36 |
| Day 7: ALT | 0.7 ± 4.69 |
| Day 10: ALT | 1.9 ± 4.11 |
| Day 4: ALP | -1.6 ± 2.00 |
| Day 7: ALP | -0.6 ± 2.39 |
| Day 10: ALP | 0.8 ± 4.06 |
| Day 4: AST | 0.9 ± 2.45 |
| Day 7: AST | -0.5 ± 2.68 |
| Day 10: AST | 0.3 ± 2.29 |
| Day 4: Gamma-glutamyl transferase | -0.8 ± 0.75 |
| Day 7: Gamma-glutamyl transferase | -0.3 ± 1.06 |
| Day 10: Gamma-glutamyl transferase | 0.5 ± 1.51 |
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Micromoles per liter | Dolutegravir 50 mg |
|---|---|
| Urate | -32.3 ± 42.01 |
| Creatinine | 5.41 ± 7.253 |
| Bilirubin | 0.01 ± 4.516 |
| Direct bilirubin | 0.03 ± 0.677 |
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Micromoles per liter | GSK3640254 200 mg |
|---|---|
| Urate | -7.1 ± 14.52 |
| Creatinine | -3.36 ± 4.219 |
| Bilirubin | 0.27 ± 1.299 |
| Direct bilirubin | 0.06 ± 0.328 |
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Micromoles per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4: Urate | 0.0 ± 16.23 |
| Day 7: Urate | -15.6 ± 26.39 |
| Day 10: Urate | -1.4 ± 24.69 |
| Day 4: Creatinine | 7.90 ± 4.239 |
| Day 7: Creatinine | 9.89 ± 4.014 |
| Day 10: Creatinine | 1.99 ± 4.739 |
| Day 4: Bilirubin | 2.24 ± 2.659 |
| Day 7: Bilirubin | -0.21 ± 1.455 |
| Day 10: Bilirubin | 1.43 ± 2.011 |
| Day 4: Direct bilirubin | 0.33 ± 0.425 |
| Day 7: Direct bilirubin | -0.19 ± 0.436 |
| Day 10: Direct bilirubin | 0.22 ± 0.248 |
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Grams per liter | Dolutegravir 50 mg |
|---|---|
| Albumin | 0.4 ± 2.45 |
| Globulin | 0.8 ± 1.11 |
| Protein | 1.2 ± 3.06 |
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Grams per liter | GSK3640254 200 mg |
|---|---|
| Albumin | 0.9 ± 1.45 |
| Globulin | -1.1 ± 0.77 |
| Protein | -0.2 ± 1.76 |
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Grams per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4: Albumin | 0.9 ± 1.00 |
| Day 7: Albumin | 0.2 ± 1.22 |
| Day 10: Albumin | 0.4 ± 2.06 |
| Day 4: Globulin | -0.9 ± 1.29 |
| Day 7: Globulin | 1.0 ± 1.10 |
| Day 10: Globulin | 0.5 ± 1.32 |
| Day 4: Protein | 0.0 ± 1.75 |
| Day 7: Protein | 1.2 ± 1.80 |
| Day 10: Protein | 0.9 ± 2.90 |
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Units per liter | Dolutegravir 50 mg |
|---|---|
| Amylase | 3.1 ± 9.63 |
| Lipase | -3.4 ± 8.97 |
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Units per liter | GSK3640254 200 mg |
|---|---|
| Amylase | -2.8 ± 4.65 |
| Lipase | -0.7 ± 3.79 |
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Units per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4: Amylase | -1.6 ± 3.18 |
| Day 7: Amylase | 0.1 ± 4.25 |
| Day 10: Amylase | -0.9 ± 6.08 |
| Day 4: Lipase | 4.7 ± 6.10 |
| Day 7: Lipase | -0.8 ± 4.76 |
| Day 10: Lipase | 0.1 ± 5.24 |
Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Ratio | Dolutegravir 50 mg |
|---|---|
| Period 1: Change From Baseline in Urinalysis Parameter: Specific Gravity | 0.0053 ± 0.00865 |
Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Ratio | GSK3640254 200 mg |
|---|---|
| Period 2: Change From Baseline in Urinalysis Parameter: Specific Gravity | -0.0004 ± 0.00645 |
Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Ratio | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 0.0003 ± 0.00652 |
| Day 7 | -0.0007 ± 0.00545 |
| Day 10 | -0.0016 ± 0.00901 |
Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Micromoles per liter | Dolutegravir 50 mg |
|---|---|
| Period 1: Change From Baseline in Urinalysis Parameter: Urobilinogen | 0.0000 ± 0.00000 |
Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Micromoles per liter | GSK3640254 200 mg |
|---|---|
| Period 2: Change From Baseline in Urinalysis Parameter: Urobilinogen | 0.0000 ± 0.00000 |
Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Micromoles per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 0.0000 ± 0.00000 |
| Day 7 | 0.0000 ± 0.00000 |
| Day 10 | 0.0000 ± 0.00000 |
Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| pH | Dolutegravir 50 mg |
|---|---|
| Period 1: Change From Baseline in Urinalysis Parameter: Potential of Hydrogen (pH) | -0.22 ± 0.730 |
Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| pH | GSK3640254 200 mg |
|---|---|
| Period 2: Change From Baseline in Urinalysis Parameter: pH | 0.13 ± 0.428 |
Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| pH | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 0.03 ± 0.531 |
| Day 7 | -0.13 ± 0.500 |
| Day 10 | 0.16 ± 0.569 |
Urine samples were collected at indicated time points to analyze parameters including glucose, protein, occult blood, ketones, nitrite, bilirubin and leukocyte esterase levels by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace, 1+ (low concentrations present) and 2+ (moderate concentrations present) indicating proportional concentrations in the urine sample.
| Participants | Dolutegravir 50 mg |
|---|---|
| Bilirubin: Negative | 16 |
| Glucose: Negative | 16 |
| Ketones: Negative | 15 |
| Ketones: Trace | 1 |
| Leukocyte Esterase: Negative | 16 |
| Nitrite: Negative | 16 |
| Occult Blood: Negative | 15 |
| Occult Blood: 2+ | 1 |
| Protein: Negative | 16 |
Urine samples were collected at indicated time points to analyze parameters including glucose, protein, occult blood, ketones, nitrite, bilirubin and leukocyte esterase levels by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace, 1+ (low concentrations present), and 2+ (moderate concentrations present) indicating proportional concentrations in the urine sample.
| Participants | GSK3640254 200 mg |
|---|---|
| Bilirubin: Negative | 16 |
| Glucose: Negative | 16 |
| Ketones: Negative | 15 |
| Ketones: 1+ | 1 |
| Leukocyte Esterase: Negative | 15 |
| Leukocyte Esterase: 1+ | 1 |
| Nitrite: Negative | 16 |
| Occult Blood: Negative | 16 |
| Protein: Negative | 16 |
Urine samples were collected at indicated time points to analyze parameters including glucose, protein, occult blood, ketones, nitrite, bilirubin and leukocyte esterase levels by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace, 1+ (low concentrations present), and 2+ (moderate concentrations present)indicating proportional concentrations in the urine sample.
| Participants | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Bilirubin: Day 4, Negative | 16 |
| Bilirubin: Day 7, Negative | 16 |
| Bilirubin: Day 10, Negative | 16 |
| Glucose: Day 4, Negative | 16 |
| Glucose: Day 7, Negative | 16 |
| Glucose: Day 10, Negative | 16 |
| Ketones: Day 4, Negative | 16 |
| Ketones: Day 7, Negative | 16 |
| Ketones: Day 10, Negative | 16 |
| Leukocyte Esterase: Day 4, Negative | 16 |
| Leukocyte Esterase: Day 7, Negative | 16 |
| Leukocyte Esterase: Day 10, Negative | 16 |
| Nitrite: Day 4, Negative | 16 |
| Nitrite: Day 7, Negative | 16 |
| Nitrite: Day 10, Negative | 16 |
| Occult Blood: Day 4, Negative | 16 |
| Occult Blood: Day 7, Negative | 16 |
| Occult Blood: Day 10, Negative | 16 |
| Protein: Day 4, Negative | 16 |
| Protein: Day 7, Negative | 16 |
| Protein: Day 10, Negative | 16 |
Twelve-lead electrocardiograms (ECG) were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments on Day 1 of Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Milliseconds | Dolutegravir 50 mg |
|---|---|
| PR Interval: Day 1, 2 hours | -0.5 ± 9.33 |
| PR Interval: Day 1, 4 hours | 1.7 ± 8.34 |
| PR Interval: Day 5, Pre-dose | 4.7 ± 6.32 |
| PR Interval: Day 5, 2 hours | 1.3 ± 8.52 |
| PR Interval: Day 5, 4 hours | 1.9 ± 12.94 |
| QRS Duration: Day 1, 2 hours | 1.8 ± 3.04 |
| QRS Duration: Day 1, 4 hours | 1.3 ± 3.32 |
| QRS Duration: Day 5, Pre-dose | -0.8 ± 3.21 |
| QRS Duration: Day 5, 2 hours | 0.8 ± 3.99 |
| QRS Duration: Day 5, 4 hours | 0.6 ± 2.78 |
| QT Interval: Day 1, 2 hours | -5.5 ± 8.21 |
| QT Interval: Day 1, 4 hours | 9.9 ± 12.91 |
| QT Interval: Day 5, Pre-dose | -6.8 ± 11.74 |
| QT Interval: Day 5, 2 hours | -16.3 ± 16.64 |
| QT Interval: Day 5, 4 hours | 1.2 ± 16.07 |
| QTcF Interval: Day 1, 2 hours | -5.0 ± 8.42 |
| QTcF Interval: Day 1, 4 hours | -1.6 ± 8.52 |
| QTcF Interval: Day 5, Pre-dose | -7.1 ± 8.53 |
| QTcF Interval: Day 5, 2 hours | -7.9 ± 9.92 |
| QTcF Interval: Day 5, 4 hours | -3.9 ± 7.56 |
| QTcB Interval: Day 1, 2 hours | -4.5 ± 10.26 |
| QTcB Interval: Day 1, 4 hours | -7.4 ± 9.16 |
| QTcB Interval: Day 5, Pre-dose | -6.7 ± 8.16 |
| QTcB Interval: Day 5, 2 hours | -3.4 ± 10.84 |
| QTcB Interval: Day 5, 4 hours | -5.9 ± 11.62 |
Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments on Day 1 of Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Milliseconds | GSK3640254 200 mg |
|---|---|
| PR Interval: Day 1, 2 hours | -3.3 ± 6.31 |
| PR Interval: Day 1, 4 hours | -3.0 ± 5.55 |
| PR Interval: Day 5, Pre-dose | -2.1 ± 6.15 |
| PR Interval: Day 5, 2 hours | -3.4 ± 7.81 |
| PR Interval: Day 5, 4 hours | -6.4 ± 6.77 |
| QRS Duration: Day 1, 2 hours | 0.1 ± 2.54 |
| QRS Duration: Day 1, 4 hours | -1.1 ± 4.08 |
| QRS Duration: Day 5, Pre-dose | 0.3 ± 3.89 |
| QRS Duration: Day 5, 2 hours | -0.2 ± 3.85 |
| QRS Duration: Day 5, 4 hours | 0.6 ± 2.70 |
| QT Interval: Day 1, 2 hours | -7.9 ± 11.47 |
| QT Interval: Day 1, 4 hours | 4.6 ± 13.48 |
| QT Interval: Day 5, Pre-dose | 2.8 ± 17.38 |
| QT Interval: Day 5, 2 hours | -7.1 ± 16.13 |
| QT Interval: Day 5, 4 hours | 6.3 ± 20.51 |
| QTcF Interval: Day 1, 2 hours | -1.3 ± 8.74 |
| QTcF Interval: Day 1, 4 hours | 3.1 ± 6.44 |
| QTcF Interval: Day 5, Pre-dose | 6.6 ± 6.79 |
| QTcF Interval: Day 5, 2 hours | 3.7 ± 9.36 |
| QTcF Interval: Day 5, 4 hours | 10.2 ± 10.44 |
| QTcB Interval: Day 1, 2 hours | 2.4 ± 13.45 |
| QTcB Interval: Day 1, 4 hours | 2.6 ± 12.62 |
| QTcB Interval: Day 5, Pre-dose | 8.4 ± 5.92 |
| QTcB Interval: Day 5, 2 hours | 9.9 ± 11.93 |
| QTcB Interval: Day 5, 4 hours | 12.4 ± 8.57 |
Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Milliseconds | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| PR Interval: Day 1, 2 hours | 1.9 ± 7.47 |
| PR Interval: Day 1, 4 hours | -1.9 ± 8.19 |
| PR Interval: Day 4, Pre-dose | -0.4 ± 6.97 |
| PR Interval: Day 4, 2 hours | 0.9 ± 8.48 |
| PR Interval: Day 4, 4 hours | -2.9 ± 9.53 |
| PR Interval: Day 5, Pre-dose | -1.4 ± 10.59 |
| PR Interval: Day 5, 2 hours | -3.2 ± 9.13 |
| PR Interval: Day 5, 4 hours | -2.7 ± 7.77 |
| PR Interval: Day 7, Pre-dose | 3.6 ± 7.61 |
| PR Interval: Day 7, 2 hours | -1.0 ± 9.47 |
| PR Interval: Day 7, 4 hours | -0.4 ± 7.61 |
| PR Interval: Day 10 | 2.3 ± 8.60 |
| QRS Duration: Day 1, 2 hours | 1.1 ± 5.47 |
| QRS Duration: Day 1, 4 hours | -2.1 ± 3.80 |
| QRS Duration: Day 4, Pre-dose | 2.0 ± 5.61 |
| QRS Duration: Day 4, 2 hours | -1.3 ± 3.09 |
| QRS Duration: Day 4, 4 hours | 0.5 ± 6.63 |
| QRS Duration: Day 5, Pre-dose | 1.8 ± 6.18 |
| QRS Duration: Day 5, 2 hours | 1.3 ± 5.11 |
| QRS Duration: Day 5, 4 hours | -0.5 ± 3.31 |
| QRS Duration: Day 7, Pre-dose | 0.6 ± 3.58 |
| QRS Duration: Day 7, 2 hours | 0.3 ± 4.93 |
| QRS Duration: Day 7, 4 hours | -0.4 ± 3.72 |
| QRS Duration: Day 10 | 1.7 ± 5.45 |
| QT Interval: Day 1, 2 hours | -7.8 ± 8.68 |
| QT Interval: Day 1, 4 hours | 4.4 ± 13.15 |
| QT Interval: Day 4, Pre-dose | 1.4 ± 14.28 |
| QT Interval: Day 4, 2 hours | -11.2 ± 14.53 |
| QT Interval: Day 4, 4 hours | 7.4 ± 13.68 |
| QT Interval: Day 5, Pre-dose | -1.4 ± 13.57 |
| QT Interval: Day 5, 2 hours | -6.9 ± 10.65 |
| QT Interval: Day 5, 4 hours | 3.9 ± 14.59 |
| QT Interval: Day 7, Pre-dose | 3.2 ± 17.34 |
| QT Interval: Day 7, 2 hours | -5.6 ± 14.01 |
| QT Interval: Day 7, 4 hours | 8.0 ± 15.38 |
| QT Interval: Day 10 | 5.1 ± 10.39 |
| QTcF Interval: Day 1, 2 hours | -0.4 ± 5.63 |
| QTcF Interval: Day 1, 4 hours | 6.6 ± 4.97 |
| QTcF Interval: Day 4, Pre-dose | 2.7 ± 8.21 |
| QTcF Interval: Day 4, 2 hours | -2.5 ± 8.41 |
| QTcF Interval: Day 4, 4 hours | 8.1 ± 9.10 |
| QTcF Interval: Day 5, Pre-dose | 6.1 ± 8.14 |
| QTcF Interval: Day 5, 2 hours | 1.1 ± 9.42 |
| QTcF Interval: Day 5, 4 hours | 8.6 ± 6.26 |
| QTcF Interval: Day 7, Pre-dose | 2.0 ± 9.21 |
| QTcF Interval: Day 7, 2 hours | 0.6 ± 7.46 |
| QTcF Interval: Day 7, 4 hours | 3.6 ± 7.28 |
| QTcF Interval: Day 10 | 1.6 ± 7.36 |
| QTcB Interval: Day 1, 2 hours | 3.8 ± 9.50 |
| QTcB Interval: Day 1, 4 hours | 7.4 ± 10.78 |
| QTcB Interval: Day 4, Pre-dose | 3.8 ± 13.72 |
| QTcB Interval: Day 4, 2 hours | -0.6 ± 17.78 |
| QTcB Interval: Day 4, 4 hours | 8.6 ± 12.83 |
| QTcB Interval: Day 5, Pre-dose | 10.6 ± 13.25 |
| QTcB Interval: Day 5, 2 hours | 5.5 ± 12.47 |
| QTcB Interval: Day 5, 4 hours | 11.3 ± 9.50 |
| QTcB Interval: Day 7, Pre-dose | 2.1 ± 14.09 |
| QTcB Interval: Day 7, 2 hours | 4.4 ± 14.43 |
| QTcB Interval: Day 7, 4 hours | 1.4 ± 10.35 |
| QTcB Interval: Day 10 | 0.2 ± 10.89 |
SBP and DBP were measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Millimeters of mercury | Dolutegravir 50 mg |
|---|---|
| SBP: Day 2 | 3.5 ± 9.97 |
| SBP: Day 3 | -0.4 ± 8.88 |
| SBP: Day 4 | 3.7 ± 11.97 |
| SBP: Day 5 | -6.2 ± 8.88 |
| DBP: Day 2 | 4.3 ± 6.70 |
| DBP: Day 3 | 0.9 ± 9.89 |
| DBP: Day 4 | 2.3 ± 8.50 |
| DBP: Day 5 | -2.6 ± 10.70 |
SBP and DBP were measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Millimeters of mercury | GSK3640254 200 mg |
|---|---|
| SBP: Day 2 | 1.7 ± 5.19 |
| SBP: Day 3 | 1.3 ± 6.83 |
| SBP: Day 4 | 3.0 ± 7.73 |
| SBP: Day 5 | -0.5 ± 5.40 |
| SBP: Day 6 | -0.1 ± 8.01 |
| SBP: Day 7 | 0.6 ± 4.57 |
| DBP: Day 2 | -0.4 ± 7.03 |
| DBP: Day 3 | 1.1 ± 4.46 |
| DBP: Day 4 | -0.4 ± 4.67 |
| DBP: Day 5 | -1.3 ± 4.85 |
| DBP: Day 6 | 0.3 ± 6.37 |
| DBP: Day 7 | 0.4 ± 5.62 |
SBP and DBP were measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Millimeters of mercury | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| SBP: Day 2 | -0.1 ± 7.66 |
| SBP: Day 3 | -3.4 ± 6.54 |
| SBP: Day 4 | -3.3 ± 6.63 |
| SBP: Day 5 | 3.6 ± 17.17 |
| SBP: Day 6 | -1.4 ± 7.08 |
| SBP: Day 7 | -2.1 ± 7.76 |
| SBP: Day 8 | -2.0 ± 9.36 |
| SBP: Day 9 | -2.3 ± 8.00 |
| SBP: Day 10 | -4.3 ± 8.35 |
| SBP: Day 11 | -3.4 ± 7.69 |
| DBP: Day 2 | 1.3 ± 3.32 |
| DBP: Day 3 | -0.1 ± 5.73 |
| DBP: Day 4 | 1.2 ± 4.51 |
| DBP: Day 5 | 6.7 ± 22.20 |
| DBP: Day 6 | 1.4 ± 6.99 |
| DBP: Day 7 | 2.9 ± 5.88 |
| DBP: Day 8 | 1.8 ± 9.89 |
| DBP: Day 9 | 2.1 ± 5.87 |
| DBP: Day 10 | 2.3 ± 4.91 |
| DBP: Day 11 | -0.1 ± 5.43 |
Pulse rate was measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Beats per minute | Dolutegravir 50 mg |
|---|---|
| Day 2 | -0.3 ± 4.30 |
| Day 3 | -1.3 ± 4.63 |
| Day 4 | 2.0 ± 8.46 |
| Day 5 | -1.6 ± 5.08 |
Pulse rate was measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Beats per minute | GSK3640254 200 mg |
|---|---|
| Day 2 | 3.9 ± 8.54 |
| Day 3 | 5.4 ± 7.19 |
| Day 4 | 4.8 ± 7.50 |
| Day 5 | 4.2 ± 8.73 |
| Day 6 | 3.8 ± 6.51 |
| Day 7 | 2.7 ± 5.78 |
Pulse rate was measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Beats per minute | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 2 | 1.8 ± 5.65 |
| Day 3 | 2.2 ± 6.88 |
| Day 4 | 0.3 ± 7.63 |
| Day 5 | 3.1 ± 7.79 |
| Day 6 | 1.3 ± 6.97 |
| Day 7 | -2.1 ± 5.94 |
| Day 8 | 2.3 ± 9.34 |
| Day 9 | -0.8 ± 7.90 |
| Day 10 | -2.9 ± 5.34 |
| Day 11 | 1.7 ± 10.56 |
Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Breaths per minute | Dolutegravir 50 mg |
|---|---|
| Day 2 | -0.9 ± 3.18 |
| Day 3 | 0.3 ± 2.05 |
| Day 4 | -1.5 ± 3.06 |
| Day 5 | -0.8 ± 2.29 |
Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Breaths per minute | GSK3640254 200 mg |
|---|---|
| Day 2, n=16 | -0.5 ± 2.58 |
| Day 3, n=16 | 0.4 ± 3.03 |
| Day 4, n=16 | -0.6 ± 3.07 |
| Day 5, n=15 | 1.3 ± 2.47 |
| Day 6, n=16 | -0.4 ± 2.55 |
| Day 7, n=16 | 0.1 ± 3.30 |
Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Breaths per minute | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 2 | 1.4 ± 3.07 |
| Day 3 | 0.5 ± 3.39 |
| Day 4 | 0.3 ± 3.34 |
| Day 5 | -0.5 ± 2.97 |
| Day 6 | 0.6 ± 3.24 |
| Day 7 | 0.3 ± 3.09 |
| Day 8 | 1.4 ± 2.80 |
| Day 9 | -0.4 ± 3.36 |
| Day 10 | 1.4 ± 2.80 |
| Day 11 | 2.8 ± 2.41 |
Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Degrees Celsius | Dolutegravir 50 mg |
|---|---|
| Day 2 | -0.04 ± 0.326 |
| Day 3 | -0.14 ± 0.287 |
| Day 4 | -0.19 ± 0.370 |
| Day 5 | 0.03 ± 0.275 |
Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Degrees Celsius | GSK3640254 200 mg |
|---|---|
| Day 2 | -0.14 ± 0.299 |
| Day 3 | -0.25 ± 0.415 |
| Day 4 | -0.19 ± 0.294 |
| Day 5 | -0.05 ± 0.363 |
| Day 6 | -0.13 ± 0.300 |
| Day 7 | -0.13 ± 0.373 |
Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Degrees Celsius | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 2 | -0.08 ± 0.286 |
| Day 3 | -0.18 ± 0.423 |
| Day 4 | 0.02 ± 0.229 |
| Day 5 | 0.00 ± 0.175 |
| Day 6 | -0.03 ± 0.318 |
| Day 7 | 0.06 ± 0.287 |
| Day 8 | -0.13 ± 0.458 |
| Day 9 | -0.10 ± 0.329 |
| Day 10 | -0.03 ± 0.291 |
| Day 11 | 0.13 ± 0.302 |
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count.
| 10^9 cells per liter | Dolutegravir 50 mg |
|---|---|
| Basophils | 0.045 ± 0.0115 |
| Eosinophils | 0.232 ± 0.1440 |
| Lymphocytes | 2.023 ± 0.5931 |
| Monocytes | 0.512 ± 0.1133 |
| Neutrophils | 3.038 ± 0.7559 |
| Platelet count | 270.2 ± 47.62 |
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count.
| 10^9 cells per liter | GSK3640254 200 mg |
|---|---|
| Basophils | 0.039 ± 0.0134 |
| Eosinophils | 0.206 ± 0.0960 |
| Lymphocytes | 1.869 ± 0.4383 |
| Monocytes | 0.488 ± 0.1081 |
| Neutrophils | 2.878 ± 0.6859 |
| Platelet count | 264.2 ± 48.37 |
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count.
| 10^9 cells per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4: Basophils, n=16 | 0.043 ± 0.0165 |
| Day 7: Basophils, n=16 | 0.046 ± 0.0196 |
| Day 10: Basophils, n=16 | 0.042 ± 0.0142 |
| Day 4: Eosinophils, n=16 | 0.206 ± 0.1120 |
| Day 7: Eosinophils, n=16 | 0.211 ± 0.1512 |
| Day 10: Eosinophils, n=16 | 0.171 ± 0.0874 |
| Day 4: Lymphocytes, n=16 | 1.739 ± 0.3701 |
| Day 7: Lymphocytes, n=16 | 1.837 ± 0.3916 |
| Day 10: Lymphocytes, n=16 | 1.753 ± 0.3450 |
| Day 4: Monocytes, n=16 | 0.537 ± 0.1821 |
| Day 7: Monocytes, n=16 | 0.490 ± 0.1157 |
| Day 10: Monocytes, n=16 | 0.470 ± 0.1128 |
| Day 4: Neutrophils, n=16 | 3.321 ± 1.4579 |
| Day 7: Neutrophils, n=16 | 2.954 ± 0.5600 |
| Day 10: Neutrophils, n=16 | 3.082 ± 0.6649 |
| Day 4: Platelet count, n=16 | 259.3 ± 46.03 |
| Day 7: Platelet count, n=15 | 255.3 ± 46.20 |
| Day 10: Platelet count, n=16 | 258.3 ± 42.92 |
Blood samples were collected to analyze the hematology parameter: hemoglobin.
| Grams per liter | Dolutegravir 50 mg |
|---|---|
| Period 1: Absolute Values for Hematology Parameter: Hemoglobin | 146.4 ± 8.02 |
Blood samples were collected to analyze the hematology parameter: hemoglobin.
| Grams per liter | GSK3640254 200 mg |
|---|---|
| Period 2: Absolute Values for Hematology Parameter: Hemoglobin | 146.5 ± 8.68 |
Blood samples were collected to analyze the hematology parameter: hemoglobin.
| Grams per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 149.8 ± 8.74 |
| Day 7 | 147.1 ± 8.23 |
| Day 10 | 147.7 ± 9.17 |
Blood samples were collected to analyze the hematology parameter: hematocrit.
| Proportion of red blood cells in blood | Dolutegravir 50 mg |
|---|---|
| Period 1: Absolute Values for Hematology Parameter: Hematocrit | 0.4419 ± 0.01697 |
Blood samples were collected to analyze the hematology parameter: hematocrit.
| Proportion of red blood cells in blood | GSK3640254 200 mg |
|---|---|
| Period 2: Absolute Values for Hematology Parameter: Hematocrit | 0.4406 ± 0.01887 |
Blood samples were collected to analyze the hematology parameter: hematocrit.
| Proportion of red blood cells in blood | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 0.4441 ± 0.01956 |
| Day 7 | 0.4357 ± 0.01924 |
| Day 10 | 0.4364 ± 0.02267 |
Blood samples were collected to analyze the hematology parameter: erythrocytes.
| Trillion cells per liter | Dolutegravir 50 mg |
|---|---|
| Period 1: Absolute Values for Hematology Parameter: Erythrocytes | 5.143 ± 0.3580 |
Blood samples were collected to analyze the hematology parameter: erythrocytes.
| Trillion cells per liter | GSK3640254 200 mg |
|---|---|
| Period 2: Absolute Values for Hematology Parameter: Erythrocytes | 5.179 ± 0.3575 |
Blood samples were collected to analyze the hematology parameter: erythrocytes.
| Trillion cells per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 5.194 ± 0.3476 |
| Day 7 | 5.099 ± 0.3798 |
| Day 10 | 5.124 ± 0.3678 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.
| Femtoliter | Dolutegravir 50 mg |
|---|---|
| Period 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume | 86.22 ± 5.670 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.
| Femtoliter | GSK3640254 200 mg |
|---|---|
| Period 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume | 85.36 ± 5.509 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.
| Femtoliter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 85.76 ± 5.323 |
| Day 7 | 85.72 ± 5.117 |
| Day 10 | 85.41 ± 5.030 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.
| Picograms | Dolutegravir 50 mg |
|---|---|
| Period 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin | 28.58 ± 2.446 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.
| Picograms | GSK3640254 200 mg |
|---|---|
| Period 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin | 28.41 ± 2.385 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.
| Picograms | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 28.96 ± 2.514 |
| Day 7 | 28.96 ± 2.404 |
| Day 10 | 28.93 ± 2.530 |
Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.
| Millimoles per liter | Dolutegravir 50 mg |
|---|---|
| Glucose | 5.165 ± 0.4788 |
| Cholesterol | 4.456 ± 0.6591 |
| Triglycerides | 1.107 ± 0.5362 |
| Anion gap | 9.2 ± 1.28 |
| Calcium | 2.393 ± 0.0781 |
| Carbon dioxide | 30.5 ± 1.15 |
| Chloride | 103.8 ± 2.32 |
| Phosphate | 1.244 ± 0.1658 |
| Potassium | 4.31 ± 0.427 |
| Sodium | 139.3 ± 2.52 |
| Blood urea nitrogen | 5.406 ± 0.7575 |
Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.
| Millimoles per liter | GSK3640254 200 mg |
|---|---|
| Glucose | 4.916 ± 0.4825 |
| Cholesterol | 4.187 ± 0.6783 |
| Triglycerides | 1.194 ± 0.7294 |
| Anion gap | 11.4 ± 1.20 |
| Calcium | 2.406 ± 0.0772 |
| Carbon dioxide | 29.3 ± 1.57 |
| Chloride | 103.1 ± 2.35 |
| Phosphate | 1.281 ± 0.1510 |
| Potassium | 4.23 ± 0.249 |
| Sodium | 139.6 ± 1.90 |
| Blood urea nitrogen | 5.065 ± 0.6775 |
Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.
| Millimoles per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4: Glucose | 4.978 ± 0.4655 |
| Day 7: Glucose | 5.018 ± 0.3977 |
| Day 10: Glucose | 4.849 ± 0.3858 |
| Day 4: Cholesterol | 4.283 ± 0.8001 |
| Day 7: Cholesterol | 4.179 ± 0.7438 |
| Day 10: Cholesterol | 4.157 ± 0.8037 |
| Day 4: Triglycerides | 1.228 ± 0.6403 |
| Day 7: Triglycerides | 1.100 ± 0.5887 |
| Day 10: Triglycerides | 1.289 ± 0.6625 |
| Day 4: Anion gap | 7.3 ± 1.01 |
| Day 7: Anion gap | 11.4 ± 1.75 |
| Day 10: Anion gap | 12.1 ± 1.31 |
| Day 4: Calcium | 2.404 ± 0.0855 |
| Day 7: Calcium | 2.433 ± 0.0827 |
| Day 10: Calcium | 2.441 ± 0.0681 |
| Day 4: Carbon dioxide | 30.2 ± 1.56 |
| Day 7: Carbon dioxide | 29.4 ± 1.15 |
| Day 10: Carbon dioxide | 30.3 ± 1.53 |
| Day 4: Chloride | 103.8 ± 2.77 |
| Day 7: Chloride | 102.8 ± 2.07 |
| Day 10: Chloride | 101.9 ± 2.02 |
| Day 4: Phosphate | 1.276 ± 0.1304 |
| Day 7: Phosphate | 1.268 ± 0.1802 |
| Day 10: Phosphate | 1.229 ± 0.1213 |
| Day 4: Potassium | 4.19 ± 0.150 |
| Day 7: Potassium | 4.19 ± 0.217 |
| Day 10: Potassium | 4.29 ± 0.275 |
| Day 4: Sodium | 137.6 ± 2.06 |
| Day 7: Sodium | 139.5 ± 2.56 |
| Day 10: Sodium | 140.1 ± 2.11 |
| Day 4: Blood urea nitrogen | 5.119 ± 0.8548 |
| Day 7: Blood urea nitrogen | 4.887 ± 0.6388 |
| Day 10: Blood urea nitrogen | 5.039 ± 0.8264 |
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.
| International units per liter | Dolutegravir 50 mg |
|---|---|
| Creatine kinase | 101.3 ± 57.10 |
| Lactate dehydrogenase | 107.4 ± 14.33 |
| ALT | 21.0 ± 10.71 |
| ALP | 57.4 ± 8.74 |
| AST | 16.6 ± 3.86 |
| Gamma-glutamyl transferase | 21.1 ± 9.24 |
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.
| International units per liter | GSK3640254 200 mg |
|---|---|
| Creatine kinase | 123.9 ± 112.28 |
| Lactate dehydrogenase | 116.5 ± 15.10 |
| ALT | 20.4 ± 9.88 |
| ALP | 59.3 ± 9.19 |
| AST | 16.8 ± 3.80 |
| Gamma-glutamyl transferase | 20.3 ± 8.44 |
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.
| International units per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4: Creatine kinase | 110.3 ± 67.02 |
| Day 7: Creatine kinase | 105.3 ± 63.83 |
| Day 10: Creatine kinase | 100.3 ± 50.51 |
| Day 4: Lactate dehydrogenase | 122.4 ± 16.26 |
| Day 7: Lactate dehydrogenase | 115.6 ± 15.47 |
| Day 10: Lactate dehydrogenase | 116.6 ± 18.79 |
| Day 4: ALT | 21.4 ± 11.98 |
| Day 7: ALT | 21.1 ± 12.00 |
| Day 10: ALT | 22.3 ± 12.93 |
| Day 4: ALP | 57.8 ± 9.34 |
| Day 7: ALP | 58.8 ± 9.63 |
| Day 10: ALP | 60.1 ± 9.07 |
| Day 4: AST | 17.7 ± 5.12 |
| Day 7: AST | 16.3 ± 4.78 |
| Day 10: AST | 17.1 ± 4.55 |
| Day 4: Gamma-glutamyl transferase | 19.5 ± 8.38 |
| Day 7: Gamma-glutamyl transferase | 20.1 ± 8.35 |
| Day 10: Gamma-glutamyl transferase | 20.8 ± 9.13 |
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.
| Micromoles per liter | Dolutegravir 50 mg |
|---|---|
| Urate | 321.9 ± 64.43 |
| Creatinine | 90.28 ± 11.281 |
| Bilirubin | 9.14 ± 2.423 |
| Direct bilirubin | 1.87 ± 0.551 |
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.
| Micromoles per liter | GSK3640254 200 mg |
|---|---|
| Urate | 314.8 ± 69.34 |
| Creatinine | 86.92 ± 11.567 |
| Bilirubin | 9.41 ± 3.014 |
| Direct bilirubin | 1.93 ± 0.704 |
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.
| Micromoles per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4: Urate | 314.8 ± 65.44 |
| Day 7: Urate | 299.3 ± 62.85 |
| Day 10: Urate | 313.4 ± 60.33 |
| Day 4: Creatinine | 94.82 ± 13.650 |
| Day 7: Creatinine | 96.81 ± 12.861 |
| Day 10: Creatinine | 88.91 ± 12.545 |
| Day 4: Bilirubin | 11.64 ± 4.856 |
| Day 7: Bilirubin | 9.19 ± 2.511 |
| Day 10: Bilirubin | 10.83 ± 3.796 |
| Day 4: Direct bilirubin | 2.26 ± 0.995 |
| Day 7: Direct bilirubin | 1.74 ± 0.617 |
| Day 10: Direct bilirubin | 2.15 ± 0.784 |
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.
| Grams per liter | Dolutegravir 50 mg |
|---|---|
| Albumin | 44.1 ± 3.32 |
| Globulin | 27.9 ± 3.59 |
| Protein | 71.9 ± 4.63 |
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.
| Grams per liter | GSK3640254 200 mg |
|---|---|
| Albumin | 44.9 ± 3.13 |
| Globulin | 26.8 ± 3.78 |
| Protein | 71.8 ± 4.73 |
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.
| Grams per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4: Albumin | 45.9 ± 3.12 |
| Day 7: Albumin | 45.1 ± 2.83 |
| Day 10: Albumin | 45.3 ± 2.80 |
| Day 4: Globulin | 25.9 ± 3.52 |
| Day 7: Globulin | 27.8 ± 3.49 |
| Day 10: Globulin | 27.3 ± 3.34 |
| Day 4: Protein | 71.8 ± 3.89 |
| Day 7: Protein | 72.9 ± 4.28 |
| Day 10: Protein | 72.6 ± 4.11 |
Blood samples were collected to analyze the chemistry parameters: amylase and lipase.
| Units per liter | Dolutegravir 50 mg |
|---|---|
| Amylase | 59.6 ± 21.96 |
| Lipase | 22.4 ± 8.57 |
Blood samples were collected to analyze the chemistry parameters: amylase and lipase.
| Units per liter | GSK3640254 200 mg |
|---|---|
| Amylase | 56.8 ± 19.06 |
| Lipase | 21.7 ± 7.34 |
Blood samples were collected to analyze the chemistry parameters: amylase and lipase.
| Units per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4: Amylase | 55.3 ± 18.81 |
| Day 7: Amylase | 56.9 ± 21.03 |
| Day 10: Amylase | 55.9 ± 20.57 |
| Day 4: Lipase | 26.4 ± 11.10 |
| Day 7: Lipase | 20.9 ± 9.12 |
| Day 10: Lipase | 21.8 ± 9.25 |
Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.
| Ratio | Dolutegravir 50 mg |
|---|---|
| Period 1: Absolute Values for Urinalysis Parameter: Specific Gravity | 1.0181 ± 0.00662 |
Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.
| Ratio | GSK3640254 200 mg |
|---|---|
| Period 2: Absolute Values for Urinalysis Parameter: Specific Gravity | 1.0176 ± 0.00552 |
Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.
| Ratio | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 1.0179 ± 0.00712 |
| Day 7 | 1.0169 ± 0.00640 |
| Day 10 | 1.0160 ± 0.00747 |
Urine samples were collected to analyze the urinalysis parameter: urobilinogen.
| Micromoles per liter | Dolutegravir 50 mg |
|---|---|
| Period 1: Absolute Values for Urinalysis Parameter: Urobilinogen | 3.3860 ± 0.00000 |
Urine samples were collected to analyze the urinalysis parameter: urobilinogen.
| Micromoles per liter | GSK3640254 200 mg |
|---|---|
| Period 2: Absolute Values for Urinalysis Parameter: Urobilinogen | 3.3860 ± 0.00000 |
Urine samples were collected to analyze the urinalysis parameter: urobilinogen.
| Micromoles per liter | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 3.3860 ± 0.00000 |
| Day 7 | 3.3860 ± 0.00000 |
| Day 10 | 3.3860 ± 0.00000 |
Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).
| pH | Dolutegravir 50 mg |
|---|---|
| Period 1: Absolute Values for Urinalysis Parameter: pH | 5.88 ± 0.465 |
Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).
| pH | GSK3640254 200 mg |
|---|---|
| Period 2: Absolute Values for Urinalysis Parameter: pH | 6.00 ± 0.548 |
Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).
| pH | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 4 | 6.03 ± 0.591 |
| Day 7 | 5.88 ± 0.387 |
| Day 10 | 6.16 ± 0.473 |
Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.
| Milliseconds | Dolutegravir 50 mg |
|---|---|
| PR Interval: Day 1, 2 hours | 159.1 ± 14.42 |
| PR Interval: Day 1, 4 hours | 161.3 ± 16.51 |
| PR Interval: Day 5, Pre-dose | 164.3 ± 14.87 |
| PR Interval: Day 5, 2 hours | 160.9 ± 11.34 |
| PR Interval: Day 5, 4 hours | 161.5 ± 12.66 |
| QRS Duration: Day 1, 2 hours | 95.2 ± 9.59 |
| QRS Duration: Day 1, 4 hours | 94.7 ± 10.90 |
| QRS Duration: Day 5, Pre-dose | 92.6 ± 8.39 |
| QRS Duration: Day 5, 2 hours | 94.2 ± 10.78 |
| QRS Duration: Day 5, 4 hours | 94.0 ± 9.26 |
| QT Interval: Day 1, 2 hours | 386.4 ± 16.06 |
| QT Interval: Day 1, 4 hours | 401.8 ± 19.94 |
| QT Interval: Day 5, Pre-dose | 385.1 ± 13.96 |
| QT Interval: Day 5, 2 hours | 375.6 ± 11.46 |
| QT Interval: Day 5, 4 hours | 393.1 ± 18.80 |
| QTcF Interval: Day 1, 2 hours | 391.6 ± 11.37 |
| QTcF Interval: Day 1, 4 hours | 395.0 ± 12.90 |
| QTcF Interval: Day 5, Pre-dose | 389.5 ± 10.92 |
| QTcF Interval: Day 5, 2 hours | 388.6 ± 14.47 |
| QTcF Interval: Day 5, 4 hours | 392.7 ± 14.11 |
| QTcB Interval: Day 1, 2 hours | 393.1 ± 15.31 |
| QTcB Interval: Day 1, 4 hours | 390.2 ± 16.01 |
| QTcB Interval: Day 5, Pre-dose | 390.9 ± 14.91 |
| QTcB Interval: Day 5, 2 hours | 394.2 ± 21.59 |
| QTcB Interval: Day 5, 4 hours | 391.7 ± 19.71 |
Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.
| Milliseconds | GSK3640254 200 mg |
|---|---|
| PR Interval: Day 1, 2 hours | 165.1 ± 15.46 |
| PR Interval: Day 1, 4 hours | 165.4 ± 14.32 |
| PR Interval: Day 5, Pre-dose | 166.3 ± 16.89 |
| PR Interval: Day 5, 2 hours | 165.0 ± 19.90 |
| PR Interval: Day 5, 4 hours | 162.0 ± 13.64 |
| QRS Duration: Day 1, 2 hours | 94.1 ± 9.66 |
| QRS Duration: Day 1, 4 hours | 92.9 ± 9.20 |
| QRS Duration: Day 5, Pre-dose | 94.3 ± 10.12 |
| QRS Duration: Day 5, 2 hours | 93.9 ± 9.00 |
| QRS Duration: Day 5, 4 hours | 94.7 ± 8.51 |
| QT Interval: Day 1, 2 hours | 381.8 ± 14.37 |
| QT Interval: Day 1, 4 hours | 394.4 ± 19.18 |
| QT Interval: Day 5, Pre-dose | 392.6 ± 23.20 |
| QT Interval: Day 5, 2 hours | 382.6 ± 17.13 |
| QT Interval: Day 5, 4 hours | 396.0 ± 21.45 |
| QTcF Interval: Day 1, 2 hours | 390.0 ± 13.74 |
| QTcF Interval: Day 1, 4 hours | 394.4 ± 12.38 |
| QTcF Interval: Day 5, Pre-dose | 397.9 ± 14.64 |
| QTcF Interval: Day 5, 2 hours | 395.0 ± 14.70 |
| QTcF Interval: Day 5, 4 hours | 401.5 ± 12.66 |
| QTcB Interval: Day 1, 2 hours | 393.3 ± 18.57 |
| QTcB Interval: Day 1, 4 hours | 393.4 ± 18.53 |
| QTcB Interval: Day 5, Pre-dose | 399.2 ± 16.61 |
| QTcB Interval: Day 5, 2 hours | 400.7 ± 20.02 |
| QTcB Interval: Day 5, 4 hours | 403.2 ± 13.41 |
Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.
| Milliseconds | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| PR Interval: Day 1, 2 hours | 167.9 ± 13.86 |
| PR Interval: Day 1, 4 hours | 164.1 ± 15.12 |
| PR Interval: Day 4, Pre-dose | 165.6 ± 16.02 |
| PR Interval: Day 4, 2 hours | 166.9 ± 15.67 |
| PR Interval: Day 4, 4 hours | 163.1 ± 15.13 |
| PR Interval: Day 5, Pre-dose | 164.6 ± 18.30 |
| PR Interval: Day 5, 2 hours | 162.8 ± 12.71 |
| PR Interval: Day 5, 4 hours | 163.3 ± 14.96 |
| PR Interval: Day 7, Pre-dose | 169.6 ± 17.47 |
| PR Interval: Day 7, 2 hours | 165.0 ± 15.69 |
| PR Interval: Day 7, 4 hours | 165.6 ± 15.00 |
| PR Interval: Day 10 | 168.3 ± 17.14 |
| QRS Duration: Day 1, 2 hours | 95.9 ± 10.49 |
| QRS Duration: Day 1, 4 hours | 92.8 ± 8.76 |
| QRS Duration: Day 4, Pre-dose | 96.8 ± 9.41 |
| QRS Duration: Day 4, 2 hours | 93.5 ± 8.21 |
| QRS Duration: Day 4, 4 hours | 95.3 ± 8.79 |
| QRS Duration: Day 5, Pre-dose | 96.6 ± 9.77 |
| QRS Duration: Day 5, 2 hours | 96.1 ± 11.66 |
| QRS Duration: Day 5, 4 hours | 94.3 ± 9.56 |
| QRS Duration: Day 7, Pre-dose | 95.4 ± 9.44 |
| QRS Duration: Day 7, 2 hours | 95.1 ± 9.52 |
| QRS Duration: Day 7, 4 hours | 94.4 ± 9.30 |
| QRS Duration: Day 10 | 96.5 ± 9.14 |
| QT Interval: Day 1, 2 hours | 380.0 ± 12.90 |
| QT Interval: Day 1, 4 hours | 392.3 ± 16.39 |
| QT Interval: Day 4, Pre-dose | 389.2 ± 18.65 |
| QT Interval: Day 4, 2 hours | 376.6 ± 18.49 |
| QT Interval: Day 4, 4 hours | 395.3 ± 17.89 |
| QT Interval: Day 5, Pre-dose | 386.4 ± 18.49 |
| QT Interval: Day 5, 2 hours | 380.9 ± 13.91 |
| QT Interval: Day 5, 4 hours | 391.8 ± 20.53 |
| QT Interval: Day 7, Pre-dose | 391.0 ± 21.99 |
| QT Interval: Day 7, 2 hours | 382.3 ± 13.85 |
| QT Interval: Day 7, 4 hours | 395.8 ± 20.94 |
| QT Interval: Day 10 | 392.9 ± 14.54 |
| QTcF Interval: Day 1, 2 hours | 392.7 ± 11.45 |
| QTcF Interval: Day 1, 4 hours | 399.7 ± 10.37 |
| QTcF Interval: Day 4, Pre-dose | 395.8 ± 13.94 |
| QTcF Interval: Day 4, 2 hours | 390.6 ± 12.33 |
| QTcF Interval: Day 4, 4 hours | 401.2 ± 13.55 |
| QTcF Interval: Day 5, Pre-dose | 399.2 ± 14.92 |
| QTcF Interval: Day 5, 2 hours | 394.3 ± 12.83 |
| QTcF Interval: Day 5, 4 hours | 401.7 ± 11.91 |
| QTcF Interval: Day 7, Pre-dose | 395.1 ± 12.91 |
| QTcF Interval: Day 7, 2 hours | 393.7 ± 12.69 |
| QTcF Interval: Day 7, 4 hours | 396.8 ± 13.47 |
| QTcF Interval: Day 10 | 394.8 ± 13.08 |
| QTcB Interval: Day 1, 2 hours | 398.4 ± 15.81 |
| QTcB Interval: Day 1, 4 hours | 402.0 ± 15.46 |
| QTcB Interval: Day 4, Pre-dose | 398.4 ± 17.82 |
| QTcB Interval: Day 4, 2 hours | 394.0 ± 21.41 |
| QTcB Interval: Day 4, 4 hours | 403.1 ± 17.67 |
| QTcB Interval: Day 5, Pre-dose | 405.1 ± 23.00 |
| QTcB Interval: Day 5, 2 hours | 400.1 ± 18.05 |
| QTcB Interval: Day 5, 4 hours | 405.9 ± 16.27 |
| QTcB Interval: Day 7, Pre-dose | 396.6 ± 17.50 |
| QTcB Interval: Day 7, 2 hours | 398.9 ± 21.21 |
| QTcB Interval: Day 7, 4 hours | 396.0 ± 18.10 |
| QTcB Interval: Day 10 | 394.8 ± 18.39 |
SBP and DBP were measured in the semi-recumbent position with a completely automated device.
| Millimeters of mercury | Dolutegravir 50 mg |
|---|---|
| SBP: Day 2 | 118.8 ± 8.57 |
| SBP: Day 3 | 114.9 ± 8.09 |
| SBP: Day 4 | 119.0 ± 9.81 |
| SBP: Day 5 | 109.1 ± 7.16 |
| DBP: Day 2 | 76.1 ± 6.53 |
| DBP: Day 3 | 72.7 ± 8.32 |
| DBP: Day 4 | 74.1 ± 8.58 |
| DBP: Day 5 | 69.2 ± 9.77 |
SBP and DBP were measured in the semi-recumbent position with a completely automated device.
| Millimeters of mercury | GSK3640254 200 mg |
|---|---|
| SBP: Day 2 | 115.8 ± 7.15 |
| SBP: Day 3 | 115.3 ± 7.57 |
| SBP: Day 4 | 117.1 ± 8.74 |
| SBP: Day 5 | 113.6 ± 7.35 |
| SBP: Day 6 | 113.9 ± 8.29 |
| SBP: Day 7 | 114.6 ± 5.73 |
| DBP: Day 2 | 69.6 ± 8.50 |
| DBP: Day 3 | 71.1 ± 7.65 |
| DBP: Day 4 | 69.6 ± 5.24 |
| DBP: Day 5 | 68.8 ± 6.49 |
| DBP: Day 6 | 70.3 ± 7.02 |
| DBP: Day 7 | 70.4 ± 6.65 |
SBP and DBP were measured in the semi-recumbent position with a completely automated device.
| Millimeters of mercury | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| SBP: Day 2 | 115.8 ± 8.12 |
| SBP: Day 3 | 112.5 ± 5.81 |
| SBP: Day 4 | 112.6 ± 6.11 |
| SBP: Day 5 | 119.4 ± 19.70 |
| SBP: Day 6 | 114.4 ± 7.45 |
| SBP: Day 7 | 113.8 ± 8.13 |
| SBP: Day 8 | 113.9 ± 6.72 |
| SBP: Day 9 | 113.6 ± 7.67 |
| SBP: Day 10 | 111.6 ± 6.38 |
| SBP: Day 11 | 112.4 ± 7.69 |
| DBP: Day 2 | 69.0 ± 6.46 |
| DBP: Day 3 | 67.7 ± 6.52 |
| DBP: Day 4 | 68.9 ± 6.33 |
| DBP: Day 5 | 74.4 ± 21.90 |
| DBP: Day 6 | 69.2 ± 8.27 |
| DBP: Day 7 | 70.6 ± 5.78 |
| DBP: Day 8 | 69.5 ± 9.34 |
| DBP: Day 9 | 69.8 ± 5.98 |
| DBP: Day 10 | 70.0 ± 5.14 |
| DBP: Day 11 | 67.7 ± 4.32 |
Pulse rate was measured in the semi-recumbent position with a completely automated device.
| Beats per minute | Dolutegravir 50 mg |
|---|---|
| Day 2 | 67.8 ± 8.47 |
| Day 3 | 66.8 ± 6.68 |
| Day 4 | 70.1 ± 10.57 |
| Day 5 | 66.4 ± 8.21 |
Pulse rate was measured in the semi-recumbent position with a completely automated device.
| Beats per minute | GSK3640254 200 mg |
|---|---|
| Day 2 | 68.3 ± 9.75 |
| Day 3 | 69.7 ± 8.65 |
| Day 4 | 69.1 ± 8.21 |
| Day 5 | 68.5 ± 11.14 |
| Day 6 | 68.1 ± 8.88 |
| Day 7 | 67.0 ± 8.95 |
Pulse rate was measured in the semi-recumbent position with a completely automated device.
| Beats per minute | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 2 | 68.4 ± 9.79 |
| Day 3 | 68.9 ± 8.63 |
| Day 4 | 66.9 ± 9.26 |
| Day 5 | 69.8 ± 10.57 |
| Day 6 | 67.9 ± 10.12 |
| Day 7 | 64.6 ± 8.02 |
| Day 8 | 69.0 ± 12.02 |
| Day 9 | 65.9 ± 10.12 |
| Day 10 | 63.8 ± 8.53 |
| Day 11 | 68.4 ± 12.27 |
Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.
| Breaths per minute | Dolutegravir 50 mg |
|---|---|
| Day 2 | 13.5 ± 1.37 |
| Day 3 | 14.6 ± 2.16 |
| Day 4 | 12.9 ± 1.78 |
| Day 5 | 13.6 ± 2.22 |
Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.
| Breaths per minute | GSK3640254 200 mg |
|---|---|
| Day 2, n=16 | 13.6 ± 0.81 |
| Day 3, n=16 | 14.5 ± 2.00 |
| Day 4, n=16 | 13.5 ± 1.15 |
| Day 5, n=15 | 15.3 ± 2.09 |
| Day 6, n=16 | 13.8 ± 2.52 |
| Day 7, n=16 | 14.3 ± 2.18 |
Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.
| Breaths per minute | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 2 | 15.0 ± 2.42 |
| Day 3 | 14.1 ± 1.54 |
| Day 4 | 13.9 ± 2.96 |
| Day 5 | 13.1 ± 1.45 |
| Day 6 | 14.3 ± 2.05 |
| Day 7 | 13.9 ± 1.86 |
| Day 8 | 15.0 ± 1.03 |
| Day 9 | 13.3 ± 3.00 |
| Day 10 | 15.0 ± 1.79 |
| Day 11 | 16.4 ± 1.31 |
Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.
| Degrees Celsius | Dolutegravir 50 mg |
|---|---|
| Day 2 | 36.36 ± 0.303 |
| Day 3 | 36.26 ± 0.287 |
| Day 4 | 36.21 ± 0.361 |
| Day 5 | 36.43 ± 0.270 |
Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.
| Degrees Celsius | GSK3640254 200 mg |
|---|---|
| Day 2 | 36.26 ± 0.339 |
| Day 3 | 36.15 ± 0.361 |
| Day 4 | 36.21 ± 0.318 |
| Day 5 | 36.35 ± 0.306 |
| Day 6 | 36.28 ± 0.309 |
| Day 7 | 36.28 ± 0.394 |
Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.
| Degrees Celsius | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Day 2 | 36.33 ± 0.284 |
| Day 3 | 36.22 ± 0.369 |
| Day 4 | 36.42 ± 0.412 |
| Day 5 | 36.40 ± 0.405 |
| Day 6 | 36.37 ± 0.366 |
| Day 7 | 36.46 ± 0.371 |
| Day 8 | 36.28 ± 0.451 |
| Day 9 | 36.30 ± 0.337 |
| Day 10 | 36.37 ± 0.294 |
| Day 11 | 36.53 ± 0.307 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Hours | GSK3640254 200 mg |
|---|---|
| Period 2: Time of Maximum Observed Concentration (Tmax) of GSK3640254 for GSK3640254 Arm | 5.000 (3.50 to 8.00) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Hours | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Period 3: Tmax of GSK3640254 for Dolutegravir + GSK3640254 Arm | 5.000 (3.50 to 8.00) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis. Data could not be determined due to limited sampling points after final dosing (during elimination phase). An accurate determination of GSK3640254 half-life would require sampling up to 3 times half-life (3 \* approximately 24 hours). However sampling in Period 2 was performed up to only 24 hours post-dose.
| Hours | GSK3640254 200 mg |
|---|---|
| Period 2: Apparent Terminal Phase Half-life (T1/2) of GSK3640254 for GSK3640254 Arm | NA ± NA |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Hours | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Period 3: T1/2 of GSK3640254 for Dolutegravir + GSK3640254 Arm | 23.417 ± 15.0 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Hours | Dolutegravir 50 mg |
|---|---|
| Period 1: Tmax of Dolutegravir for Dolutegravir Arm | 3.000 (1.00 to 4.50) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Hours | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Period 3: Tmax of Dolutegravir for Dolutegravir + GSK3640254 Arm | 3.000 (1.00 to 4.50) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Hours | Dolutegravir 50 mg |
|---|---|
| Period 1: T1/2 of Dolutegravir for Dolutegravir Arm | 14.492 ± 11.8 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.
| Hours | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|
| Period 3: T1/2 of Dolutegravir for Dolutegravir + GSK3640254 Arm | 14.690 ± 12.1 |
Collected over Non-SAEs and SAEs were collected from start of the study treatment up to Day 27. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dolutegravir 50 mg | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| GSK3640254 200 mg | 0/16 (0%) | 0/16 (0%) | 3/16 (18.8%) |
| Dolutegravir 50 mg + GSK3640254 200 mg | 0/16 (0%) | 0/16 (0%) | 2/16 (12.5%) |
| Event | Dolutegravir 50 mg | GSK3640254 200 mg | Dolutegravir 50 mg + GSK3640254 200 mg |
|---|---|---|---|
| DermatitisSkin and subcutaneous tissue disorders | 0/16 | 0/16 | 1/16 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/16 | 0/16 | 1/16 |
| Keratosis pilarisSkin and subcutaneous tissue disorders | 0/16 | 1/16 | 0/16 |
| Medical device site dermatitisGeneral disorders | 0/16 | 1/16 | 1/16 |
| FatigueGeneral disorders | 0/16 | 0/16 | 1/16 |
| Ear pruritusEar and labyrinth disorders | 0/16 | 0/16 | 1/16 |
| Skin abrasionInjury, poisoning and procedural complications | 1/16 | 0/16 | 0/16 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/16 | 1/16 | 0/16 |
| AnxietyPsychiatric disorders | 0/16 | 1/16 | 0/16 |
| Age, Continuous(Years) | Dolutegravir/GSK3640254/Dolutegravir+GSK3640254 |
|---|---|
| Mean | 36.7 ± 10.66 |
| Sex: Female, Male(Participants) | Dolutegravir/GSK3640254/Dolutegravir+GSK3640254 |
|---|---|
| Female | 1 |
| Male | 15 |
| Race/Ethnicity, Customized(Participants) | Dolutegravir/GSK3640254/Dolutegravir+GSK3640254 |
|---|---|
| Asian - East Asian Heritage | 1 |
| Asian - South East Asian Heritage | 1 |
| Black or African American | 3 |
| White - White/Caucasian/European Heritage | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jan 2019 to primary completion in Mar 2019, 2 months.
Results were first posted in Mar 2020, 11 months after primary completion.
Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 2 months is below that.
Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: GSK3640254 · Dolutegravir